AGIO
Price:
$55.68
Market Cap:
$3.18B
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2013-07-24
Stock Exchange
NASDAQ
Ticker
AGIO
According to Agios Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.99. This represents a change of -18.61% compared to the average of 11.05 of the last 4 quarters.
The mean historical Current Ratio of Agios Pharmaceuticals, Inc. over the last ten years is 8.65. The current 8.99 Current Ratio has changed 10.29% with respect to the historical average. Over the past ten years (40 quarters), AGIO's Current Ratio was at its highest in in the June 2021 quarter at 28.07. The Current Ratio was at its lowest in in the December 2017 quarter at 4.69.
Average
8.65
Median
6.57
Minimum
4.69
Maximum
17.79
Discovering the peaks and valleys of Agios Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 163.74%
Maximum Annual Current Ratio = 17.79
Minimum Annual Increase = -25.93%
Minimum Annual Current Ratio = 4.69
Year | Current Ratio | Change |
---|---|---|
2023 | 12.27 | -7.72% |
2022 | 13.30 | -25.25% |
2021 | 17.79 | 163.74% |
2020 | 6.74 | 2.42% |
2019 | 6.59 | 0.32% |
2018 | 6.56 | 39.97% |
2017 | 4.69 | -25.93% |
2016 | 6.33 | -0.74% |
2015 | 6.38 | 8.37% |
2014 | 5.89 | 28.05% |
The current Current Ratio of Agios Pharmaceuticals, Inc. (AGIO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
14.45
5-year avg
11.34
10-year avg
8.65
Agios Pharmaceuticals, Inc.’s Current Ratio is greater than Mereo BioPharma Group plc (6.10), greater than Blueprint Medicines Corporation (3.32), less than Day One Biopharmaceuticals, Inc. (14.62), greater than BioMarin Pharmaceutical Inc. (4.27), less than IDEAYA Biosciences, Inc. (22.93), less than AnaptysBio, Inc. (10.23), greater than MeiraGTx Holdings plc (2.34), less than Keros Therapeutics, Inc. (19.03), greater than Homology Medicines, Inc. (4.19), greater than Kymera Therapeutics, Inc. (8.55), less than Revolution Medicines, Inc. (14.24), greater than C4 Therapeutics, Inc. (6.31), greater than Nurix Therapeutics, Inc. (5.28), less than Relay Therapeutics, Inc. (18.42), greater than Stoke Therapeutics, Inc. (5.09), less than Pliant Therapeutics, Inc. (10.26), greater than Black Diamond Therapeutics, Inc. (5.55), greater than Arvinas, Inc. (4.17), greater than Syndax Pharmaceuticals, Inc. (6.99), greater than Cogent Biosciences, Inc. (6.44), less than Cullinan Oncology, Inc. (24.46), greater than KalVista Pharmaceuticals, Inc. (8.55), greater than Mersana Therapeutics, Inc. (2.35),
Company | Current Ratio | Market cap |
---|---|---|
6.10 | $575.61M | |
3.32 | $5.98B | |
14.62 | $1.38B | |
4.27 | $12.25B | |
22.93 | $2.32B | |
10.23 | $677.65M | |
2.34 | $463.45M | |
19.03 | $2.27B | |
4.19 | $3.02M | |
8.55 | $2.91B | |
14.24 | $9.55B | |
6.31 | $300.00M | |
5.28 | $1.56B | |
18.42 | $795.07M | |
5.09 | $605.41M | |
10.26 | $789.88M | |
5.55 | $143.73M | |
4.17 | $1.78B | |
6.99 | $1.37B | |
6.44 | $1.01B | |
24.46 | $730.17M | |
8.55 | $494.46M | |
2.35 | $252.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agios Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Agios Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Agios Pharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for Agios Pharmaceuticals, Inc. (AGIO)?
What is the highest Current Ratio for Agios Pharmaceuticals, Inc. (AGIO)?
What is the 3-year average Current Ratio for Agios Pharmaceuticals, Inc. (AGIO)?
What is the 5-year average Current Ratio for Agios Pharmaceuticals, Inc. (AGIO)?
How does the current Current Ratio for Agios Pharmaceuticals, Inc. (AGIO) compare to its historical average?